Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage, ALK-positive non-small cell lung cancer (NSCLC).
The approval is significant for patients with this type of lung tumour, as nearly half of them will experience a relapse despite undergoing surgery and adjuvant chemotherapy to try to stop the cancer from recurring.
